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OBJECTIVE—The progressive inﬁltration of pancreatic islets
by lymphocytes is mandatory for development of autoimmune
type 1 diabetes. This inﬂammatory process is mediated by several
mediators that are potential therapeutic targets to arrest devel-
opment of type 1 diabetes. In this study, we investigate the role
of one of these mediators, interleukin-16 (IL-16), in the patho-
genesis of type 1 diabetes in NOD mice.
RESEARCH DESIGN AND METHODS—At different stages of
progression of type 1 diabetes, we characterized IL-16 in islets
using GEArray technology and immunoblot analysis and also
quantitated IL-16 activity in cell migration assays. IL-16 expres-
sion was localized in islets by immunoﬂuorescence and confocal
imaging. In vivo neutralization studies were performed to assess
the role of IL-16 in the pathogenesis of type 1 diabetes.
RESULTS—The increased expression of IL-16 in islets corre-
lated with the development of invasive insulitis. IL-16 immuno-
reactivity was found in islet inﬁltrating T-cells, B-cells, NK-cells,
and dendritic cells, and within an insulitic lesion, IL-16 was
derived from inﬁltrating cells. CD4
 and CD8
 T-cells as well as
B220
 B-cells were identiﬁed as sources of secreted IL-16.
Blockade of IL-16 in vivo protected against type 1 diabetes by
interfering with recruitment of CD4
 T-cells to the pancreas, and
this protection required the activity of the chemokine CCL4.
CONCLUSIONS—IL-16 production by leukocytes in islets aug-
ments the severity of insulitis during the onset of type 1 diabetes.
IL-16 and CCL4 appear to function as counterregulatory proteins
during disease development. Neutralization of IL-16 may repre-
sent a novel therapy for the prevention of type 1 diabetes.
Diabetes 59:2862–2871, 2010
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nsulitis and type 1 diabetes are mediated by the
regulated homing of leukocytes to pancreatic islets
by chemoattractants (1–3). Unlike chemokines that
bind chemokine receptors, the interleukin-16 (IL-16)
cytokine binds to CD4 and selectively recruits CD4
 T
helper one (Th1) cells due to the functional relationship
between CD4 and the CCR5 and CXCR3 chemokine recep-
tors (4,5). Mature IL-16 is secreted after caspase-3 medi-
ated cleavage of either neuronal IL-16 or precursor protein
(pro-IL-16) (6–13). IL-16 also regulates T-cell activation,
CD25 and major histocompatibility complex class II ex-
pression, IL-2 production (14), antigen-induced upregula-
tion of CD95 expression (14), and chemokine-induced
chemoattraction (15,16). Binding of IL-16 to CD4 selec-
tively desensitizes CCL4/CCR5-induced chemotaxis, and
pretreatment of T-cells with CCL4 blocks chemotaxis
triggered by IL-16 binding to CD4 (15). CD4 and CCR5 may
therefore share a unique relationship mediated by either
IL-16 and/or CCL4 binding, and IL-16 and CCL4 may
cross-regulate each other’s activity. Thus, IL-16 is an
immunomodulatory and proinﬂammatory cytokine that
inﬂuences the recruitment and activation of CD4
 T-cells
in vivo.
Given that CD4
 T-cells mediate the development of
type 1 diabetes, we examined whether IL-16 inﬂuences
CD4
 T-cell recruitment to pancreatic islets. We show that
IL-16 potentiates insulitis and type 1 diabetes in NOD
mice, and that anti-IL-16 antibody therapy protects against
type 1 diabetes even when administered at the mid-late
stages of disease progression. This protection results from
reduced trafﬁcking of CD4
 T-cells to islet lesions and
requires CCL4 activity. Thus, IL-16 may represent a novel
therapeutic target for the prevention of type 1 diabetes.
RESEARCH DESIGN AND METHODS
NOD/Del, NOD.Scid, and NOD.RAGKO mice were housed at the Robarts
Research Institute (London, ON, Canada). C57BL/6J mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). The NOD-BDC2.5.Thy1.1
mice were a kind gift of the Bluestone laboratory at the University of
California San Francisco. Mice were maintained in a speciﬁc pathogen-free
barrier facility according to Institutional guidelines.
Reagents. The 14.1 (mouse IgG2a[]) and 17.1 (mouse IgG1) anti-IL-16
monoclonal antibodies (mAbs), which react with mouse and human IL-16,
were puriﬁed from ascites on a Protein A afﬁnity column (15).
GEArray technology. Changes in gene expression were analyzed using
GEArray technology according to the manufacturer’s directions (Super-
Array Biosciences). A detailed protocol is presented in the supplemen-
tary Material and Methods, available in an online appendix at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-0131/DC1.
In vivo treatment of mice. NOD mice were injected intraperitoneally 3 times
weekly with the 14.1 anti-IL-16 neutralizing mAb as follows: either 0.1 mg from
3–16 weeks of age or 0.2 mg from 3 to 7, 9 to 16, or 17 to 22 weeks of age.
Control mice received isotype-matched mouse IgG2a() (UPC 10, 200 g,
Sigma) (17). To determine whether CCL4 mediates anti-IL-16 induced protec-
tion from type 1 diabetes, 0.2 mg of anti-IL-16 (14.1) and 0.1 mg of anti-mouse
CCL4 mAb (R&D Systems) were coadministered 3 times weekly from 9 to 16
weeks of age. Control mice received isotype-matched control IgG2a() (UPC
10) and rat IgG (Sigma). A blood glucose level (BGL) of 11.1 mmol/l on two
consecutive readings indicated the onset of type 1 diabetes.
Histopathology. Pancreata were ﬁxed in 10% buffered formalin, embedded in
parafﬁn, and sectioned at 7 m intervals. The incidence and severity of
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2862 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.orginsulitis were examined after hematoxylin–eosin (H&E) staining. At least 10
nonadjacent sections were analyzed per pancreas, and average percentages of
insulitis were determined from 100 islets per treatment group.
Adoptive T-cell transfer. NOD.Scid mice (5–7 weeks old, n  8/group) were
injected intraperitoneally with spleen T-cells (4  10
6 per mouse) isolated at
16 weeks of age from NOD mice treated 3 times weekly from 9 to 16 weeks of
age with 200 g of anti-IL-16 (14.1) or isotype control IgG2a().
Statistical analysis. Signiﬁcant differences were determined using the
Student t test for unpaired samples, the Mantel-Haenszel log-rank test, and the
Mann-Whitney nonparametric test where indicated. Statistical comparisons
were performed using GraphPad Prism (www.graphpad.com; San Diego, CA).
A probability value of P  0.05 was considered signiﬁcant.
A supplementary Research Design and Methods section is available in the
online appendix.
RESULTS
IL-16 expression during development of insulitis. In
our NOD female mice, nondestructive peri-insulitis devel-
ops from 6 to 10 weeks of age and is followed by an
invasive and destructive insulitis in 15–25-week-old mice
(Fig. 1A). Onset of diabetes is observed as early as 13
weeks of age, progressing to a cumulative disease inci-
dence of 80–90% by 30 weeks of age. Cytokine GEArray
analyses of changes in islet cytokine expression revealed
that, relative to 3-week-old mice, IL-16 mRNA was in-
creased 2-fold in 9-week-old mice and reached a maxi-
mum by 15 weeks of age (Fig. 1B). IL-16 mRNA expression
decreased between 15 and 25 weeks of age, even though
insulitis persists during this period. This may reﬂect a
reduced number of total islet inﬁltrating leukocytes result-
ing from the destruction of a majority of islets by this age.
The above-described analyses of intra-islet IL-16
mRNA detected expression of all IL-16 isoforms. We
therefore characterized the IL-16 protein isoforms in the
pancreas and islets at progressive stages of insulitis,
noting that only the mature IL-16 isoform is secreted
and chemotactic for CD4
 cells. Initially, IL-16 was
immunoprecipitated from islet and pancreas lysates
between 3 and 19 weeks of age. Intrapancreatic pro-
IL-16 (80 kDa) expression increased during this time-
frame and peaked near 16 weeks of age (Fig. 1B).
Similarly, mature IL-16 (18 kDa) was detected between
8 and 16 weeks of age. Because a very low level of 80
kDa pro-IL-16 was detected in the pancreas of NOD.Scid
mice (Fig. 1C), IL-16 is expressed in the pancreas in the
absence of insulitis and increases with disease progres-
sion. To more accurately quantitate the levels of mature
IL-16, IL-16 was enriched from pancreas and islet lysates
by immunoafﬁnity chromatography and assayed for its
ability to induce CD4
 T-cell chemotaxis. This enabled
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FIG. 1. Quantitation of IL-16 mRNA and chemotactic activity in the pancreas and islets. A: Severity of insulitis in female NOD mice at the indicated
ages. B: GEArray analysis of intra-islet IL-16 mRNA in total islet RNA isolated at the indicated ages. The relative amount of IL-16 transcript at
each age was estimated by comparing its average signal intensity with the average signal derived from glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and normalized to 3 weeks of age. One of two representative experiments is shown. C: Immunoprecipitation of IL-16 isoforms in
pancreata from NOD and NOD.Scid (NS) mice. Lysate aliquots were immunoprecipitated as described in RESEARCH DESIGN AND METHODS. All blots
were initially developed by electrochemiluminescence. Visualization of mature IL-16 was enhanced by stripping, reblotting, and detecting with the
more sensitive ECL-Plus reagent (lower panel). Stripping and reblotting with nonspeciﬁc isotype-matched biotinylated control failed to detect
IL-16. Results are from one of three representative and reproducible experiments. D: Production of bioactive IL-16 in the pancreas and islets.
IL-16 chemoattractant activity was analyzed at the indicated ages using a modiﬁed Boyden chamber assay. For the indicated ages, puriﬁed splenic
T-cells (5  10
6) were incubated with either immunoafﬁnity-isolated IL-16 samples from islets and pancreas (black bars) or a neutralizing
anti-IL-16 mAb (5 g/ml; white bars). *Indicates IL-16 induced chemotaxis was signiﬁcantly neutralized by anti-IL-16, P < 0.05. **Denotes
signiﬁcant IL-16-induced chemotaxis at the indicated ages, P < 0.05. Similar results were obtained in two independent and reproducible
experiments.
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approaches, e.g., ELISA, that due to the limited speci-
ﬁcities of commercially available antibodies do not
differentiate among the various IL-16 isoforms. For each
lysate, IL-16 was enriched using an equivalent amount of
total protein. IL-16 chemotactic activity in the islets and
pancreas increased signiﬁcantly among 3 and 15 weeks
of age, with the largest increase detected between 9 and
15 weeks (Fig. 1D). Note that IL-16 activity was reduced
appreciably by 26 weeks of age, indicative of the
destruction of the majority of islets at this time of islet
isolation. The speciﬁcity of IL-16–induced T-cell chemo-
taxis was demonstrated by the capacity of the 14.1
neutralizing anti-IL-16 mAb to abrogate this chemotactic
response. Thus, levels of mature IL-16 in islets increase
in an age-dependent manner, suggesting that mature
IL-16 is associated with proinﬂammatory responses
against islets.
In situ localization of IL-16 in islets. To examine which
cells produce IL-16 in an insulitic lesion, immunohisto-
chemistry and confocal imaging was used. Because IL-16
is synthesized as pro-IL-16 and cleaved only by activated
caspase-3 to produce mature IL-16 (10), cells secreting
IL-16 were identiﬁed by triple immunostaining for IL-16,
active caspase-3, and various cell surface markers of
immune cells. IL-16 immunoreactivity was found in a
majority of mononuclear cells in insulitic lesions, includ-
ing Thy1
 T-cells, B220
 B-cells, CD4
 and CD8
 T-cells,
p46
 NK-cells, and CD11c
 dendritic cells (Fig. 2 and
supplementary Fig. 1, available in an online appendix). For
all experiments, the appropriate isotype controls were
used to rule out nonspeciﬁc staining (supplementary Fig.
2A, available in an online appendix). As determined by
colocalized staining for activated caspase-3, Thy1
 T-cells,
B220
 B-cells, and both CD4
 and CD8
 T-cells produce
mature IL-16. Colocalization of IL-16 and activated
caspase-3 occurred mainly in a polarized manner. While
many lymphocytes constitutively express pro-IL-16, only a
low frequency of lymphocytes stained for activated
caspase-3, in support of our immunoprecipitation studies
that displayed a low level of mature IL-16 in the pancreas.
Because IL-16 expression was not detected in insulin-
producing islet -cells, IL-16 production appears to be
restricted to immune cells in an islet lesion in support of
our ﬁnding that IL-16 is not expressed in islets from
NOD.RAGKO mice (supplementary Fig. 2B). Thus, in an
insulitic lesion, mature IL-16 is secreted by several types of
immune cells, and this may enable these cells to recruit
additional CD4
 T-cells to an islet lesion and augment an
ongoing inﬂammatory response.
Neutralizing anti-IL-16 mAb prevents insulitis and
type 1 diabetes. Having determined that intra-islet ex-
pression of mature IL-16 increases with the severity of
insulitis, we next examined whether blockade of endoge-
nous IL-16 can prevent type 1 diabetes. NOD mice were
treated with a neutralizing anti-IL-16 mAb or isotype-
matched control antibody from 3 to 16 weeks of age when
intrapancreatic levels of IL-16 are increased. This treat-
ment reduced the overall severity of insulitis and pre-
vented the onset of destructive insulitis as insulin
expression was preserved (Fig. 3A). In comparison to
33-week-old NOD mice treated with isotype control anti-
body (group 1), the percentage of islets (14%) displaying
severe insulitis (insulitis score  3) in anti-IL-16 treated
mice (group 2) was signiﬁcantly less than that observed
(53%) in control mice. Anti-IL-16 treated mice still pos-
sessed 52% normal healthy islets (insulitis score  0),
whereas only 20% of islets were healthy in the control-
treated mice. In addition, the incidence of type 1 diabetes
was reduced from 88% (16/18 mice) in control-treated mice
to 44% (8/18 mice; P  0.004) in anti-IL-16 treated mice at
33 weeks of age (Fig. 3B). These data show that neutral-
ization of IL-16 protects against insulitis and type 1
diabetes.
Because intrapancreatic IL-16 expression peaks be-
tween 9 and 16 weeks of age, we reasoned that neutral-
ization of IL-16 may prevent type 1 diabetes more
effectively during this time than at a younger age when
intra-islet levels of mature IL-16 are low. To test this
possibility, anti-IL-16 or control antibody was adminis-
tered during either 3–7 weeks of age, 9–16 weeks of age, or
after the onset of invasive insulitis. At 33 weeks of age, a
similar incidence of type 1 diabetes was initially observed
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FIG. 2. In situ localization of IL-16 to lymphocytes in islets of 10-week-
old NOD mice. Pancreas sections were stained with anti-IL-16 (red; all
panels), anti-activated caspase-3 (blue; C–E, I, J, M, and N), anti-
insulin (blue; F, L, and O), and various cell surface markers in green
(Thy1.2 in A, D, and E; B220 in G, J, and K; CD4 in M and N). Magniﬁed
images of areas indicated by the white boxes in merged images (D, J,
and M) are presented in E, K, and N. Colocalized signals of IL-16,
activated caspase-3, and Thy1.2 (E) or B220 (K) or CD4 (N) are
denoted by arrows. Adjacent serial sections stained for IL-16 and
insulin are shown in F, L, and O. Scale bars represent 50 m for all
images except for the magniﬁed images (E, K, N), where the scale bar
represents 10 m. (A high-quality digital representation of this ﬁgure
is available in the online issue.)
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either 100 or 200 g of anti-IL-16 mAb per injection (8/18 
44%, Fig. 3B; and 3/8  37.5%, data not shown), respec-
tively. Thus, a dose range of 100–200 g per injection is
most effective for neutralization of IL-16. As short treat-
ment regimens were used, mice were injected with a
two-fold higher dose of antibody than that used for longer
treatments (3–16 weeks of age). Compared with control
mice treated from 9 to 16 weeks of age (group 3; H&E
images not shown), anti-IL-16 treatment prevented the
development of destructive insulitis (group 4) with protec-
tion being equally effective to that in mice treated with
FIG. 3. Neutralization of IL-16 prevents destructive insulitis and type 1 diabetes in NOD mice in a time- and dose-dependent manner. A:
Representative H&E- and insulin-stained pancreas sections from NOD mice at 33 weeks of age previously treated three times weekly from 3 to
16 weeks of age with 100 g of isotype control (1) or anti-IL-16 (2), or from 9 to 16 weeks of age with 200 g isotype control (3) (note: H&E
images are not shown) or anti-IL-16 (4). At 33 weeks, the severity of insulitis was similar for mice treated with isotype control antibody from 9
to 16 (3) or 3 to 16 weeks of age (1). Bar graphs represent the percent of islets in each insulitis scoring category for each denoted treatment
group. A representative islet of the most prevalent insulitis score observed for each treatment group at 33 weeks of age is presented. More than
100 islets were analyzed for each treatment group. NOD mice treated three times weekly with anti-IL-16 from either 3 to 16 (B)( P  0.005) or
9 to 16 weeks of age (C)( P  0.015), but not from 3 to 7 (D)( P  0.45) or 17 to 22 weeks of age (E)( P  0.19), are protected against type 1
diabetes compared with control-treated mice. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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the incidence of type 1 diabetes was reduced (P  0.015)
by 50% in the 9–16-week-old anti-IL-16 treated mice (4/12
mice  33%) relative to control-treated mice (10/12 mice 
83%) (Fig. 3C). In contrast, anti-IL-16 did not prevent type
1 diabetes (P  0.451) when administered between 3 and
7 weeks of age (Fig. 3D). In addition, anti-IL-16 treatment
from 17–22 weeks of age (after disease onset when severe
insulitis predominates) was ineffective (P  0.194) at
protecting against type 1 diabetes (Fig. 3E). Note that the
median survival time of 26 weeks in anti-IL-16 treated mice
exceeded that of 19 weeks in control-treated mice. There-
fore, IL-16 activity is not critical for the initiation of disease
but is important for the transition from noninvasive to
destructive insulitis. Neutralization of IL-16 during this tran-
sition elicits maximum protection against type 1 diabetes.
Anti-IL-16 treatment decreases T-cell activation in
the pancreatic lymph nodes and diminishes T-cell
recruitment to islets. Because IL-16 recruits CD4
 T-
cells to sites of inﬂammation and mature IL-16 levels
increase more than threefold in the islets and pancreas of
3–15-week-old NOD mice, we analyzed whether anti-IL-16
treatment from 9 to 16 weeks of age protects from type 1
diabetes by blocking the recruitment to and activation of
CD4
 T-cells in the pancreas. Consistent with our result
that anti-IL-16 therapy from 9–16 weeks of age prevents
invasive insulitis and type 1 diabetes, CD69 expression on
CD4
 (P  0.010) and CD8
 T-cells (P  0.012) from the
pancreatic lymph nodes (PLN) of 16 week-old mice was
signiﬁcantly lower in anti-IL-16 than control-treated mice
(Fig. 4A). Thus, T-cells in anti-IL-16 treated mice are less
activated at the time of destructive insulitis. Moreover, a
lower percentage of CD3
 T-cells and higher percentage of
B220
 B-cells was detected in islets of anti-IL-16 treated
versus control-treated mice (supplementary Fig. 3A, avail-
able in an online appendix), decreasing the CD3
/B220

ratio of islet-inﬁltrating cells from 2.2 to 1.1. Although
B220
CD11c
neg immunosuppressive dendritic-like cells
can prevent type 1 diabetes (18), we did not detect an
increased frequency of this cellular subset in the pancreas
of anti-IL-16 treated mice (supplementary Fig. 3B). In
addition, a signiﬁcant decrease occurred in the total
number of islet-inﬁltrating CD4
 (P  0.021) and CD8

(P  0.001) T-cells in anti-IL-16 treated mice without any
signiﬁcant change in the number of B220
 B-cells (P 
0.464) (Fig. 4B), suggesting a preferential inhibitory effect
on T-cells. Because CD4 can function as a chemotactic
receptor for IL-16 on co-stimulated CD8
 T-cells (19),
neutralization of IL-16 may diminish the recruitment of
activated CD8
 T-cells to islets. Interestingly, a signiﬁ-
cantly altered chemokine proﬁle was also observed in the
PLN of anti-IL-16 treated mice (supplementary Table 1,
available in an online appendix). Comparative analyses of
changes in gene expression of 96 different cytokines and
chemokines and their receptors performed using GEArray
technology revealed that the expression of several tran-
scripts, including CXCR1, CXCR3, CCR4, CCR5, CXCL9,
CXCL10, CXCL12, CCL22, and macrophage migration in-
hibitory factor (MIF), was decreased 2-fold in anti-IL-16
versus control-treated mice. The activities of MIF, CCL22,
CXCL10, CXCL12, ligands for CCR4 (CCL22), CCR5
(CCL5), and CXCR3 (CXCL10) have been associated with
the development of type 1 diabetes (2,3,20–24). Only CCL4
and IL-10 mRNA expression was upregulated in the PLN of
anti-IL-16 versus control-treated mice, which supports our
later result that T-cell production of CCL4 is enhanced in
the PLN of mice protected from type 1 diabetes. Note that,
while a detectable increase in frequency of CD4
 IL-10

T-cells in the PLN of anti-IL-16 treated mice was not
detected, the mean ﬂuorescent intensity (MFI) was in-
creased, indicating that CD4
 T-cells produce more IL-10
on a per cell basis. Moreover, in contrast to the spleen,
diminished Th1-like responses were observed in the PLN
of anti-IL-16 treated mice (supplementary Fig. 4, available
in an online appendix). Thus, neutralization of IL-16 is
associated with the decreased expression of several in-
ﬂammatory gene transcripts in the PLN, where autoreac-
tive T-cells may encounter antigen before migrating to
islets and eliciting their destruction (25).
Diabetogenic potential of spleen T-cells is reduced in
anti-IL-16 treated mice. Adoptive transfer studies were
conducted to investigate whether a decrease in the diabe-
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FIG. 4. Anti-IL-16 protective therapy inhibits T-cell activation in the pancreas and islet inﬁltration by T-cells. A: Independent groups of NOD mice
were treated with anti-IL-16 (f) or control antibody (F) 3 times per week from 9 to 16 weeks of age, at which time PLN-derived T-cells were
pooled from seven groups of three mice immediately after treatment. Surface CD69 expression was then determined using ﬂow cytometry (*P <
0.003; **P < 0.02). B: NOD mice (n  6–8/group) were treated as above and the frequencies of islet-inﬁltrating lymphocytes were determined
by ﬂow cytometry, allowing for lymphocyte cell numbers per pancreas to be calculated. The numbers of islet inﬁltrating lymphocytes per mouse
obtained in three experiments were [(2.5, 2.8, 3.1)  10
5] for anti-IL-16 and [(3.4, 3.8, 2.9)  10
5] for control-treated mice. Numbers in the bars
indicate the fold change for the particular T-cell subset (*P < 0.03).
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induced protection against type 1 diabetes. Transfer of
type 1 diabetes was signiﬁcantly prevented (P  0.011) in
NOD.Scid recipients of spleen T-cells from anti-IL-16
treated NOD mice (16 weeks old) (Fig. 5). Whereas only
25% (2/8) of recipients of spleen T-cells from anti-IL-16
treated mice developed type 1 diabetes by 12 weeks after
transfer, 100% (8/8) of NOD.Scid recipients of spleen
T-cells from control-treated mice developed type 1 diabe-
tes by 8 weeks after transfer. Thus, the diabetogenic
potential of splenic T-cells is diminished appreciably in
anti-IL-16–treated mice at 16 weeks of age. Because we
did not detect a signiﬁcant increase in the number of
regulatory T-cells in the spleen of anti-IL-16 treated mice
(our unpublished data), another mechanism(s) may con-
trol the diabetogenic potential of T-cells in anti-IL-16
treated mice.
Anti-IL-16 therapy elicits Th1-like immune responses
and susceptibility of T-cells to apoptosis. Because
Th2-type cytokine responses can prevent type 1 diabetes
(26), we considered whether a heightened Th2-type im-
mune response develops in anti-IL-16 treated mice. Unex-
pectedly, activated spleen T-cells from anti-IL-16 treated
mice produced signiﬁcantly more IL-2 (P  0.008), IFN-
(P  0.001), and CCL4 (P  0.004) than T-cells from
control-treated mice (Fig. 6A). However, no changes in the
level of IL-4 were detected (our unpublished data). Simi-
larly, activated T-cells secreted elevated levels of CCL4,
but not IL-4, in the PLN of anti-IL-16 treated mice (Fig. 6B).
Administration of CCL4 directly prevents type 1 diabetes
in NOD mice (27). Moreover, elevated levels of IFN- in
the spleen diminish the autoimmune response in NOD
mice by promoting the activation-induced cell death
(AICD) of T-cells (28). Considering that IL-16 regulates
susceptibility of CD4
 T-cells to apoptosis (7), we deter-
mined whether anti-IL-16 enhances the apoptosis of T-cell
receptor (TCR)-stimulated spleen cells. At 48 h poststimu-
lation, signiﬁcantly higher levels of apoptotic NOD spleen
CD4
 T-cells (P  0.008) were detected in anti-IL-16 than
in control-treated mice (Fig. 6C). Therefore, anti-IL-16 may
protect from type 1 diabetes by enhancing CD4
 T-cell
susceptibility to apoptosis in response to TCR stimulation.
Anti-IL-16 therapy inhibits the activation of autore-
active T-cells in the pancreas. To further test the
hypothesis that anti-IL-16 therapy regulates the recruit-
ment and activation of islet-speciﬁc CD4
 T-cells in the
pancreas, we compared the levels of antigen-induced
T-cell proliferation in the pancreas of anti-IL-16 and
isotype control-treated mice. NOD mice were treated
with anti-IL-16 or isotype control antibody between 3 and
15 weeks of age. At 14 weeks of age, both groups of NOD
mice received CD4
CD25
neg T-cells from NOD.
BDC2.5 Thy1.1
 mice. At 7 days posttransfer, 73.5% of islet
antigen speciﬁc Thy1.1
BDC2.5 T-cells were dividing in
the pancreas of isotype-treated mice compared to only
0.01% of the corresponding T-cells in anti-IL-16 treated
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appendix). Minimal proliferation was observed in antigen-
deﬁcient inguinal lymph nodes (IGLN) in either isotype
control or anti-IL-16 treated recipient mice. These results
indicate that anti-IL-16 therapy inhibits the proliferation of
islet antigen-speciﬁc T-cells in the pancreas.
Neutralization of CCL4 abrogates anti-IL-16–in-
duced protection against type 1 diabetes. Because
CCL4 protects from type 1 diabetes (27) and spleen- and
PLN-T-cell production of CCL4 is elevated in anti-IL-16
mAb treated mice, we determined whether anti-IL-16–
induced protection from type 1 diabetes occurs in a
CCL4-dependent manner. The effect of coadministration of
neutralizing anti-CCL4 and anti-IL-16 antibodies to female
NOD mice from 9 to 16 weeks of age on the incidence of
type 1 diabetes was evaluated. This combination treatment
abrogated (P  0.05) the ability of anti-IL-16 to protect
against type 1 diabetes (Fig. 7). Thus, anti-IL-16 therapy
augments CCL4 production by T-cells, and anti-IL-16 me-
diated protection against type 1 diabetes is
CCL4-dependent.
DISCUSSION
In this study, we demonstrate that progression to the onset
of type 1 diabetes in NOD mice is associated with an
increased expression of IL-16 in pancreatic islets and
identify IL-16 as a novel potential target for protection
against the development of type 1 diabetes. Our studies
localized mature IL-16 to B-cells and T-cells in islet lesions
and detected IL-16 only during the development of inva-
sive and destructive insulitis up to 15–16 weeks of age.
Importantly, the secretion of IL-16 by several cell types in
islet lesions can potentially augment the autoimmune
response by recruiting additional CD4
 cells, including
various T-cell populations and dendritic cells, to sites of
islet damage. Consistent with this idea, treatment of
pre-diabetic NOD mice with a neutralizing anti-IL-16 mAb
beginning at the outset of mature IL-16 expression in islets
resulted in lower numbers of activated CD4
 T-cells in the
pancreas and provided optimum protection against de-
structive insulitis and type 1 diabetes. Consequently, we
have demonstrated for the ﬁrst time that neutralization of
endogenous IL-16 activity may have therapeutic value for
the treatment of type 1 diabetes because of its ability to
arrest the transition from peri-insulitis to an invasive/
destructive insulitis and onset of disease. This notion
builds on the relationship between therapeutic efﬁcacy
and stage of disease treatment recommended for transla-
tional efﬁciency in clinical trials of type 1 diabetes (29).
Furthermore, this relationship may apply for other suc-
cessful modes of anti-IL-16 mediated protection, e.g.,
inﬂammation and disease in the experimental allergic
encephalomyelitis (EAE) mouse model of multiple sclero-
sis and in a mouse model of inﬂammation-mediated isch-
emia–reperfusion injury of the kidney (30–32).
Although our study is the ﬁrst to characterize the
function of IL-16 during the development of type 1
diabetes, earlier reports have described how adminis-
tration of a nondepleting anti-CD4 mAb also prevents
type 1 diabetes (33,34). Similar to anti-IL-16 immuno-
therapy, this nondepleting anti-CD4 mAb prevents type
1 diabetes when administered after the development of
invasive insulitis (33). The latter studies agree with our
results considering that such an anti-CD4 mAb may
block IL-16/CD4 interactions, and the efﬁcacy of a
nondepleting anti-CD4 mAb may be due in part to the
inhibition of IL-16 function.
IL-16 can suppress CD4
 T-cell activation and AICD (7),
and such mechanisms may promote inﬂammation and/or
autoimmunity by regulating T-cell homeostasis and limit-
ing the clonal expansion of autoreactive T-cells (35,36). In
NOD mice, the development of type 1 diabetes is inﬂu-
enced by defects in central and peripheral tolerance
including TCR-stimulated CD4
 T-cell resistance to apop-
tosis (37–41). Here, we showed that neutralization of IL-16
enhances TCR-induced susceptibility of spleen CD4
 T-
cells to apoptosis. Although the mechanism that regulates
apoptosis of CD4
 T-cells in anti-IL-16 treated mice is
unknown, previous studies predict that CD95 may play a
role (7). In addition, IFN- may also regulate T-cell apop-
tosis and homeostasis in anti-IL-16 treated mice given that
we found an increased production of IFN- by spleen
T-cells from anti-IL-16 versus control-treated mice. The
latter ﬁnding is consistent with reports that IFN- induces
the apoptosis of effector Th1 cells (42), triggers CD4

T-cell AICD (43,44), and protects from type 1 diabetes by
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NOD mice (28). Furthermore, we observed that spleen
T-cells from anti-IL-16 treated mice were deﬁcient in their
ability to transfer type 1 diabetes to NOD.Scid mice. Thus,
by enhancing susceptibility of CD4
 effector T-cells to
apoptosis together with neutralization of IL-16 chemotac-
tic activity, anti-IL-16 therapy may reduce CD4
 T-cell
trafﬁcking to islets by different mechanisms. Moreover, the
reduced severity of islet inﬁltration by CD4
 and CD8

T-cells in anti-IL-16 treated NOD mice is also accompanied
by the decreased expression of several other inﬂammatory
cytokines, chemokines, and their receptors in the pan-
creas (supplementary Table 1). Although neutralization of
IL-16 protects from type 1 diabetes, we also noted that
some anti-IL-16 treated mice developed type 1 diabetes at
the same age as control-treated mice. It is likely that
several other chemoattractant factors also target the im-
mune system against islets in the absence of IL-16, which
is consistent with the pleiotropic and redundant biology of
chemoattractant cytokines.
A diminished inﬂammatory response against islets and
prevention of type 1 diabetes seems to result in part from
the decreased expression of several inﬂammatory media-
tors. Nonetheless, neutralization of IL-16 led to an increase
in CCL4 and IL-10 expression in the PLN, which is relevant
because CCL4 and IL-10 expression are associated with
protection against type 1 diabetes. Of note, whereas acti-
vated T-cells were found to secrete elevated levels of CCL4
in the PLN of anti-IL-16 treated mice, CCL4 is also ex-
pressed by a variety of immune cells that could represent
additional cellular sources of CCL4 in anti-IL-16 treated
mice. Because we showed that neutralization of CCL4
reverses anti-IL-16 mediated protection against type 1
diabetes, our results agree with several reports that CCL4
protects against type 1 diabetes in mice and is not associ-
ated with disease onset in humans (22,27,45,46). Although
an increase in the frequency of FoxP3
 regulatory T-cells
was not observed in anti-IL-16 treated mice, we cannot
exclude the possibility that Tr1 regulatory T-cells and their
secreted IL-10 product may be protective in these mice, as
comparison of the IL-10 MFI indicated that CD4
 T-cells
do indeed produce greater amounts of IL-10 in the PLN of
anti-IL-16 treated mice (supplementary Fig. 4).
Because CD4 and CCR5 can act synergistically to
selectively recruit Th1 cells to sites of inﬂammation
(4,47), CCL4 expression may be elevated in anti-IL-16
treated mice to compensate for deﬁcient IL-16 activity.
However, if IL-16 and CCL4 function cooperatively to
promote islet inﬂammation, then neutralization of CCL4
would not be expected to abrogate anti-IL-16 mediated
protection. Thus, our results support the notion that
IL-16 may regulate or antagonize CCL4 function in the
spleen and islets during the onset of type 1 diabetes.
These ﬁndings are consistent with the observations that
reciprocal cross-desensitization occurs between CD4
and CCR5 upon the binding of IL-16 and CCL4, respec-
tively (15), and that CCL4 treatment can prevent type 1
diabetes (27). How CCL4 functions in anti-IL-16–in-
duced protection from type 1 diabetes is currently not
well understood, but this protection may result from the
lack of IL-16–induced desensitization of CCR5 accord-
ing to a model shown in Fig. 8 (4,15). This model
proposes that CCL4 signaling through CCR5 mediates
protection from type 1 diabetes, an idea supported by
two recent reports that transient blockade of CCR5 with
an anti-CCR5 mAb during 11–13 weeks of age or CCR5
deﬁciency signiﬁcantly accelerates rather than prevents
type 1 diabetes in NOD mice (48,49). Further experimen-
tation is required to ascertain the functional role of
CCL4 in anti-IL-16 mediated protection against type 1
diabetes.
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